Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00704977
Other study ID # sor471508ctil
Secondary ID
Status Recruiting
Phase N/A
First received June 24, 2008
Last updated June 24, 2008
Start date June 2008
Est. completion date July 2010

Study information

Verified date June 2008
Source Soroka University Medical Center
Contact Tova Lifshitz, MD
Phone 972-8-6400288
Email Toval@bgu.ac.il
Is FDA regulated No
Health authority Israel: Ethics Commission
Study type Interventional

Clinical Trial Summary

Purpose of this study is to evaluate efficiency and safety of Alcohol 20% for peeling pterygium and to compare 3 different methods of operative wound closure: Bare sclera, Sliding flap, Amniotic membrane + biological glue


Description:

Pterygium is a fibrovascular tissue growing on conjunctiva and cornea. The disturbance/morbidity caused by pterygium is diverse, ranging from mild esthetic disturbance and till recurrent inflammations and significant decrease of visual acuity. Rate of pterygium is between 20%-49% of general population, while increase in these numbers is observed in the population of equatorial regions. Pterygium usually appears at age of 22-49 years. While the rate of pterygium appearance increases with the age, the recurrence rate after surgical removal is higher in younger patients. Treatment of pterygium is surgical. The main challenges during surgery are peeling of pterygium and prevention of recurrence. During the last two decades several methods were developed and became widely accepted for pterygium surgery. The emphasis in modifying pterygium surgery is done on initial phase of surgery - techniques of pterygium separation and the final phase - the wound closure methods, additionally adjuncts (such as Mitomycine C) became widely used. These modifications are considered to improve the surgical outcomes and decrease the rate of complications and recurrence rate. Currently popular techniques of pterygium separation include Blunt dissection + keratectomy (blunt separation of the tissue + dissection of superficial layers of cornea); Avulsion technique (Avulsion of the pterygium head by creating tension on the cap edge+ further optional blunt dissection); Air assisted dissection (injection of air into the side of pterygium cap to create good separation plane).

Alcohol 20% is widely used in surface refractive surgery, where it helps to peel easily the epithelium of the cornea. Several reports show a positive role of alcohol in treatment of recurrent corneal erosions resistant to other treatments. At microscopic level - the ethanol splits basement membrane at the level between lamina lucida and lamina densa, additionally ethanol destroys the hemidesmosome junctions between epithelial cells. No consensus exists on ethanol influence on keratocyte viability and function: some studies show delayed wound healing and significant keratocyte damage, while other works show no significant alteration in keratocyte number while using alcohol.

At the phase of pterygium separation our purpose is to check the safety and efficiency of alcohol 20% for peeling of pterygium from ocular surface.

Various closure techniques exist, 3 of the widespread techniques are: Bare sclera (with adjunct such as mitomycine C) - the wound is left as it is, without closure. Sliding conjunctival flap- conjunctiva from adjacent region is dissected, moved to the wound area and sutured. Amniotic membrane transplantation, using biological glue to adhere the membrane. Amniotic membrane does not carry HLA antigens - so that no HLA compatibility tests are needed. Amniotic membrane underwent screening of infectious diseases and was cryopreserved. Amniotic membrane is applied with its mesenchimal part towards sclera and basement membrane side upwards. Adhesion of amniotic membrane is achieved by biological glue (containing thrombin and calcium as main ingredients)

We intend to compare each of these methods of wound closure in conjunction with using alcohol 20 % for pterygium separation.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date July 2010
Est. primary completion date July 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age- above 18 years old.

- Primary pterygium.

- Eligibility to sign the informed consent.

Exclusion Criteria:

- Unwillingness to participate in study.

- Hypersensitivity to materials/ medications used during the surgery.

- Pregnancy.

- Cases when the eye which should be operated is the only fuctional eye.

- Age less than 18 years old.

- Recurrent pterygium.

- Chronic eye diseases, especially ocular surface disorders such as: OCP, severe blepharitis, severe keratoconjunctivitis,atopic eye disorders.

Patients which are not eligible to sign independently the informed consent.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique
The eye operated is disinfected and covered according routine protocol. Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS. Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS. Wound closure by by technique described in each arm. Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment. Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks. Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs.

Locations

Country Name City State
Israel Soroka University Medical Center Beer Sheva
Israel Soroka University Medical Center, Ophthalmology department and outpatient clinics Beer Sheva

Sponsors (1)

Lead Sponsor Collaborator
Soroka University Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary postoperative complications during first 3 months Yes
Primary pterygium recurrence at least 1 year No
Secondary patient satisfaction during 1 year No
Secondary corneal topography during 1 year No
Secondary endothelial cell density during 1 year Yes
Secondary evaluation of risk factors for pterygium recurrence (ex. exposure to UV-light, family history ...) during 1 year Yes
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02641132 - Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count. Phase 4
Completed NCT02342392 - Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study Phase 2/Phase 3
Recruiting NCT01387971 - Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders N/A
Recruiting NCT05978687 - The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision Phase 4
Not yet recruiting NCT06042296 - Expression of CD44, PCNA and E-cadherin in Pterygium Tissue
Completed NCT04022811 - Effect of Bromfenac on Pain Related to Pterygium Surgery Phase 4
Recruiting NCT01261455 - Prospective Randomized Pilot Study Comparing Inferior Versus Superior Conjunctival Autografts for Primary Pterygia N/A
Recruiting NCT01249235 - Bandage Contact Lens and Oral Analgesics Versus Patching and Oral Analgesics for Pain Following Pterygium Surgery N/A
Completed NCT01115517 - Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery Phase 2
Completed NCT00768963 - Ranibizumab for the Inhibition of Neovascularization in Pterygia Phase 1
Completed NCT00949728 - Conjunctival Autologous Transplantation Using Fibrin Glue in Primary Pterygia N/A
Recruiting NCT00563277 - Surgical Treatment of Concurrent Cataract and Primary Pterygium N/A
Completed NCT00346450 - Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Phase 3
Completed NCT03533244 - A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia Phase 2
Completed NCT04403516 - Dextenza in Pterygium Surgery Phase 4
Recruiting NCT02911532 - Tissue Engineering Conjunctiva for the Treatment of Pterygium and Atretoblepharia N/A
Not yet recruiting NCT03304366 - Corneal Changes With Pentacam Before and After Pterygium N/A
Unknown status NCT02015000 - Surgical Result of Pterygium Extended Removal Followed by Fibrin Glue Assisted Amniotic Membrane Transplantation N/A
Completed NCT00344201 - Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery Phase 1
Recruiting NCT00326560 - Comparison of Glue With Sutures for Pterygium Surgery Phase 3